278 related articles for article (PubMed ID: 28560593)
1. Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Eng OS; Dumitra S; O'Leary M; Wakabayashi M; Dellinger TH; Han ES; Lee SJ; Benjamin Paz I; Singh G; Lee B
Ann Surg Oncol; 2017 Sep; 24(9):2707-2711. PubMed ID: 28560593
[TBL] [Abstract][Full Text] [Related]
2. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
Charrier T; Passot G; Peron J; Maurice C; Gocevska S; Quénet F; Eveno C; Pocard M; Goere D; Elias D; Ortega-Deballon P; Vaudoyer D; Cotte E; Glehen O
Ann Surg Oncol; 2016 Jul; 23(7):2315-22. PubMed ID: 26920385
[TBL] [Abstract][Full Text] [Related]
4. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
[TBL] [Abstract][Full Text] [Related]
6. Association of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
Eng OS; Dumitra S; O'Leary M; Raoof M; Wakabayashi M; Dellinger TH; Han ES; Lee SJ; Paz IB; Lee B
JAMA Surg; 2017 Dec; 152(12):1156-1160. PubMed ID: 28832866
[TBL] [Abstract][Full Text] [Related]
7. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
[TBL] [Abstract][Full Text] [Related]
8. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases.
Chua TC; Quinn LE; Zhao J; Morris DL
J Surg Oncol; 2013 Aug; 108(2):81-8. PubMed ID: 23737041
[TBL] [Abstract][Full Text] [Related]
9. Postoperative Complications Independently Predict Cancer-Related Survival in Peritoneal Malignancies.
Choudry MHA; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2018 Dec; 25(13):3950-3959. PubMed ID: 30302637
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
Chemama S; Bayar MA; Lanoy E; Ammari S; Stoclin A; Goéré D; Elias D; Raynard B; Antoun S
Ann Surg Oncol; 2016 Nov; 23(12):3891-3898. PubMed ID: 27352205
[TBL] [Abstract][Full Text] [Related]
11. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
12. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
[TBL] [Abstract][Full Text] [Related]
13. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Somashekhar SP; Yethadka R; Kumar C R; Ashwin KR; Zaveri S; Rauthan A
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):577-581. PubMed ID: 31677939
[TBL] [Abstract][Full Text] [Related]
14. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
Bhagwandin SB; Naffouje S; Salti G
J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA
Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489
[TBL] [Abstract][Full Text] [Related]
16. Surgical Treatment of Colorectal Cancer with Peritoneal and Liver Metastases Using Combined Liver and Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Report from a Single-Centre Experience.
Navez J; Remue C; Leonard D; Bachmann R; Kartheuser A; Hubert C; Coubeau L; Komuta M; Van den Eynde M; Zech F; Jabbour N
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):666-673. PubMed ID: 27646023
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive Surgery and HIPEC in an Enhanced Recovery After Surgery Program: A Feasibility Study.
Lu PW; Fields AC; Shabat G; Bleday R; Goldberg JE; Irani J; Stopfkuchen-Evans M; Melnitchouk N
J Surg Res; 2020 Mar; 247():59-65. PubMed ID: 31767280
[TBL] [Abstract][Full Text] [Related]
18. Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies.
Dreznik Y; Hoffman A; Hamburger T; Ben-Yaacov A; Dux Y; Jacoby H; Berger Y; Nissan A; Gutman M
Surgeon; 2018 Oct; 16(5):278-282. PubMed ID: 29429947
[TBL] [Abstract][Full Text] [Related]
19. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
[TBL] [Abstract][Full Text] [Related]
20. Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis.
Paredes AZ; Guzman-Pruneda FA; Abdel-Misih S; Hays J; Dillhoff ME; Pawlik TM; Cloyd JM
J Surg Res; 2019 Sep; 241():31-39. PubMed ID: 31004870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
